203 related articles for article (PubMed ID: 10027330)
1. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
[TBL] [Abstract][Full Text] [Related]
2. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
3. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Takamori K; Igawa K; Yoshida M; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
[TBL] [Abstract][Full Text] [Related]
4. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
[TBL] [Abstract][Full Text] [Related]
5. A prognostic value of syndecan-1 in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
Anticancer Res; 2000; 20(6D):4905-7. PubMed ID: 11326638
[TBL] [Abstract][Full Text] [Related]
6. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
7. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
8. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
9. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck.
Inki P; Joensuu H; Grénman R; Klemi P; Jalkanen M
Br J Cancer; 1994 Aug; 70(2):319-23. PubMed ID: 8054282
[TBL] [Abstract][Full Text] [Related]
10. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes.
Inki P; Larjava H; Haapasalmi K; Miettinen HM; Grenman R; Jalkanen M
Eur J Cell Biol; 1994 Feb; 63(1):43-51. PubMed ID: 8005104
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of syndecan-1 expression in breast cancer.
Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
[TBL] [Abstract][Full Text] [Related]
12. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis.
Chen CL; Ou DL
Hum Pathol; 2006 Oct; 37(10):1279-85. PubMed ID: 16949936
[TBL] [Abstract][Full Text] [Related]
13. Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue.
Ro Y; Muramatsu T; Shima K; Yajima Y; Shibahara T; Noma H; Shimono M
Int J Oral Maxillofac Surg; 2006 Mar; 35(3):252-7. PubMed ID: 16280239
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
[TBL] [Abstract][Full Text] [Related]
15. Parotid metastasis--an independent prognostic factor for head and neck cutaneous squamous cell carcinoma.
Ch'ng S; Maitra A; Lea R; Brasch H; Tan ST
J Plast Reconstr Aesthet Surg; 2006; 59(12):1288-93. PubMed ID: 17113505
[TBL] [Abstract][Full Text] [Related]
16. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
18. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
Zellweger T; Ninck C; Mirlacher M; Annefeld M; Glass AG; Gasser TC; Mihatsch MJ; Gelmann EP; Bubendorf L
Prostate; 2003 Apr; 55(1):20-9. PubMed ID: 12640657
[TBL] [Abstract][Full Text] [Related]
19. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
20. Head and neck squamous cell carcinoma: the role of post-operative adjuvant radiotherapy.
Dinshaw KA; Agarwal JP; Laskar SG; Gupta T; Shrivastava SK; Cruz AD
J Surg Oncol; 2005 Jul; 91(1):48-55. PubMed ID: 15999358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
